Fierce Biotech May 3, 2024
Conor Hale

The infectious disease diagnostic developer Karius has secured another $100 million to help expand the reach of its microbial DNA test designed to detect more than 1,000 different pathogens from a single blood sample.

The Fierce Medtech Fierce 15 winner previously raised $165 million in February 2020, just before the coronavirus behind COVID-19 landed with full effect on U.S. shores.

The Redwood City, California-based company said the latest funds will help move the Karius test outside of the hospital setting, where it’s currently being employed by about 400 locations and more than 6,000 physicians—largely at cancer centers, where patients can carry heightened risks to bacteria, fungi, parasites and viruses. Karius estimates that about 60% of deaths among people with...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Investments, Medical Devices, Trends
How new tariffs on Chinese medical products will affect US healthcare
PCOS infertility treatment developer May Health raises $25M
Medical device instructions need a rewrite, APIC says
Dexcom details plans for over-the-counter CGM as insulin pump firms seek Type 2 coverage
Jabra Enhance Launches Smallest OTC Hearing Aid

Share This Article